comparemela.com

Latest Breaking News On - Vitro techniques - Page 4 : comparemela.com

Hemostemix Inc : Hemostemix Announces $2,750,000 Convertible Debenture

Calgary, Alberta (Newsfile Corp. - March 2, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce that it has signed a binding term sheet

Thomas smeenkVenture exchange theCommon shares of the company debentureRegulation service providerCommon shares of the companyWorld economic forum technology pioneer awardHemostemix incAlberta newsfile corpVenture exchangeBoard of directors the companyEach debenture unitCommon sharesCommon shareMarket priceConversion priceEach debenture warrant

Hemostemix Inc : Hemostemix Announces Closing of UNIT Private Placement

Calgary, Alberta (Newsfile Corp. - February 28, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") announces that it has closed its previously announced non-brokered private

Thomas smeenkRegulation service providerCommon shares of the companyWorld economic forum technology pioneer awardHemostemix incAlberta newsfile corpVenture exchangeCompany common shareEach unitCommon shareCommon sharesMultilateral instrumentMinority security holdersSpecial transactionsIschemic cardiomyopathyDilated cardiomyopathy

Hemostemix Inc : Hemostemix Announces Financing

Calgary, Alberta (Newsfile Corp. - February 2, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce a non-brokered private placement of up to 7,200

Thomas smeenkAlberta securities commission ruleRegulation service providerWorld economic forum technology pioneer awardHemostemix incAlberta newsfile corpVenture exchangeCompany common shareEach unitCommon shareCommon sharesMultilateral instrumentMinority security holdersSpecial transactionsExisting security holdersIschemic cardiomyopathy

Hemostemix Inc : Hemostemix Partners with My Next Health, Obtains USD $150,000 Subscription at CAD $0 25 Per Unit, and Incorporates Functional Genomics

Calgary, Alberta (Newsfile Corp. - January 21, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce it has signed a Global Master Services

Thomas smeenkRichard heinzlRegulation service providerWorld economic forum technology pioneer awardHemostemix incMy next health incMy next healthAlberta newsfile corpGlobal master services agreementVenture exchangeNext healthIschemic cardiomyopathyStem cell treatmentRegulating stem cellsVitro techniquesStem cells

Hemostemix Inc : Hemostemix to Combine ACP-01 with Dr James Shapiro s Islet Cells to Treat Type 1 Diabetes

Calgary, Alberta (Newsfile Corp. - January 11, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce it has signed a contract with Dr.

Thomas smeenkJames shapiroFraser hendersonRoyal society of canadaUniversity of albertaRoyal college of surgeons englandRegulation service providerDepartment of surgeryWorld economic forum technology pioneer awardHemostemix incCanada research councilAlberta newsfile corpVenture exchangeEngland journalHunterian medalRoyal college

vimarsana © 2020. All Rights Reserved.